We must stay alert and seek to reconcile the inevitable dilemmas that arise as technology offers new opportunities in research and development and as societal attitudes and norms change.
Bioethics is the term we use for all ethical issues related to the use of life science technologies for the discovery, development and production of pharmaceutical products. It is of utmost importance to Novo Nordisk, that we in the process of bringing a new product to the market, carefully consider the ethical implications of our research and development activities as well as being attentive to societal concerns. We focus on ethical issues related to:
Clinical trials and the use of human biosamples including stem cells in research.
Reduction, refinement and replacement of animal research.
Gene technology used in research and production.
Recognising and understanding the ethical implications of our business is an ongoing process. Bioethical considerations are a natural part of our decision-making processes and we have learnt from engagements with stakeholders. This approach has enabled us to raise ethical standards, frame the Novo Nordisk Bioethics Policy and positions, and to develop new guidelines and working procedures.
In 2014 the company’s TBL Quarterly provided valuable insight into how Novo Nordisk conducts research in a responsible way and makes a positive contribution to health, society and the environment.